Bailey HH - Search Results

1

Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.

Anderson CP, Seeger RC, Satake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP. Anderson CP, et al. Among authors: bailey hh. J Pediatr Hematol Oncol. 2001 Nov;23(8):500-5. doi: 10.1097/00043426-200111000-00007. J Pediatr Hematol Oncol. 2001. PMID: 11878777

2

Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.

Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP. Anderson CP, et al. Among authors: bailey hh. Pediatr Blood Cancer. 2015 Oct;62(10):1739-46. doi: 10.1002/pbc.25594. Epub 2015 Jul 7. Pediatr Blood Cancer. 2015. PMID: 26153194 Clinical Trial.

3

Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.

Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR. Bailey HH, et al. J Clin Oncol. 1994 Jan;12(1):194-205. doi: 10.1200/JCO.1994.12.1.194. J Clin Oncol. 1994. PMID: 8270977 Clinical Trial.

4

Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.

Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G. Bailey HH, et al. J Natl Cancer Inst. 1997 Dec 3;89(23):1789-96. doi: 10.1093/jnci/89.23.1789. J Natl Cancer Inst. 1997. PMID: 9392620 Clinical Trial.

5

L-S,R-buthionine sulfoximine: historical development and clinical issues.

Bailey HH. Bailey HH. Chem Biol Interact. 1998 Apr 24;111-112:239-54. doi: 10.1016/s0009-2797(97)00164-6. Chem Biol Interact. 1998. PMID: 9679558

6

Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels.

Mulcahy RT, Bailey HH, Gipp JJ. Mulcahy RT, et al. Among authors: bailey hh. Cancer Chemother Pharmacol. 1994;34(1):67-71. doi: 10.1007/BF00686114. Cancer Chemother Pharmacol. 1994. PMID: 7513621

7

Transfection of complementary DNAs for the heavy and light subunits of human gamma-glutamylcysteine synthetase results in an elevation of intracellular glutathione and resistance to melphalan.

Mulcahy RT, Bailey HH, Gipp JJ. Mulcahy RT, et al. Among authors: bailey hh. Cancer Res. 1995 Nov 1;55(21):4771-5. Cancer Res. 1995. PMID: 7585502

8

Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels.

Bailey HH, Gipp JJ, Ripple M, Wilding G, Mulcahy RT. Bailey HH, et al. Cancer Res. 1992 Sep 15;52(18):5115-8. Cancer Res. 1992. PMID: 1355406

9

Increased expression of gamma-glutamyl transpeptidase in transfected tumor cells and its relationship to drug sensitivity.

Bailey HH, Gipp JJ, Mulcahy RT. Bailey HH, et al. Cancer Lett. 1994 Dec 9;87(2):163-70. doi: 10.1016/0304-3835(94)90218-6. Cancer Lett. 1994. PMID: 7812936

10

Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.

Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, Harris L, Jumonville A, Hansen R, Shapiro GR, Stewart JA. Bailey HH, et al. Cancer Chemother Pharmacol. 2008 Jun;62(1):149-57. doi: 10.1007/s00280-007-0585-6. Epub 2007 Sep 21. Cancer Chemother Pharmacol. 2008. PMID: 17885756 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

86 results

Search Page